Senescence in premalignant tumours
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Oncogene-induced senescence is a cellular response that may be crucial for protection against cancer development, but its investigation has so far been restricted to cultured cells that have been manipulated to overexpress an oncogene. Here we analyse tumours initiated by an endogenous oncogene, ras, and show that senescent cells exist in premalignant tumours but not in malignant ones. Senescence is therefore a defining feature of premalignant tumours that could prove valuable in the diagnosis and prognosis of cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lastly, in mice and humans, a senescence response to strong mitogenic signals, such as those delivered by certain oncogenes, prevents premalignant lesions from progressing to malignant cancers [ 16 – 19 ].”
From Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor (2008) · cites this paper as [16]
In the citing paper
“In addition to identifying known cell-cycle regulators, these studies identified DCR2 as a common marker of senescence (Collado et al., 2005), later shown to characterize other types of senescence.”
From Cellular Senescence: Defining a Path Forward (2019) · cites this paper as Collado et al., 2005
In the citing paper
“OIS or senescence induced by loss of a tumor suppressor was verified in vivo in human and murine preneoplastic lesions (Collado et al., 2005; Gorgoulis and Halazonetis, 2010; Kuilman and Peeper, 2009) and primary or treated neoplasias (Haugstetter et al., 2010).”
From Cellular Senescence: Defining a Path Forward (2019) · cites this paper as Collado et al., 2005
In the citing paper
“Studies in various mouse models, supported by correlative evidence from human- derived tissue samples, have underscored the tumour- suppressive role of OIS 81,120-123 .”
From Senescence and cancer — role and therapeutic opportunities (2022) · cites this paper as [122]
In the citing paper
“This type of oncogene-induced senescence (OIS) is frequently observed in premalignant and benign tumour tissues [37 -39] but not in advanced malignant tumours, where cancer cells have already bypassed senescence.”
From The role of cellular senescence and SASP in tumour microenvironment (2023) · cites this paper as [38]
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
Self-citationRb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence
Narita, M., Nuñez, S., Heard, E., Narita, M., Lin, A. W., Hearn, S. A., Spector, D. L., Hannon, G. J., & Lowe, S. W. (2003) · Cell · doi:10.1016/s0092-8674(03)00401-x · Cited by 2,278
Lowe, S. W., Cepero, E., & Evan, G. (2004) · Nature · doi:10.1038/nature03098 · Cited by 1,309
Tuveson, D. A., Shaw, A. T., Willis, N. A., Silver, D. P., Jackson, E. L., Chang, S., Mercer, K. L., Grochow, R., Hock, H., Crowley, D., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00085-6 · Cited by 798
p19ARF links the tumour suppressor p53 to Ras
Palmero, I., Pantoja, C., & Serrano, M. (1998) · Nature · doi:10.1038/25870 · Cited by 615
Self-citationTumor induction by an endogenous K-ras oncogene is highly dependent on cellular context
Guerra, C., Mijimolle, N., Dhawahir, A., Dubus, P., Barradas, M., Serrano, M., Campuzano, V., & Barbacid, M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00191-0 · Cited by 571
Self-citation
Cited by
Items 401–500 of 1,005
Autophagy at the intersection of aging, senescence, and cancer
Cassidy, L. D., & Narita, M. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13269 · Cited by 84
Tissue factor is a critical regulator of radiation therapy-induced glioblastoma remodeling
Jeon, H.-M., Kim, J., Cho, H. J., Lee, W. J., Nguyen, D., Kim, S. S., Oh, Y. T., Kim, H., Jung, C., Piñero, G., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.06.007 · Cited by 102
Emerging insights in senescence: pathways from preclinical models to therapeutic innovations
Mansfield, L., Ramponi, V., Gupta, K., Stevenson, T., Mathew, A. B., Barinda, A. J., Herbstein, F., & Morsli, S. (2024) · npj Aging · doi:10.1038/s41514-024-00181-1 · Cited by 88
Byun, H.-O., Han, N.-K., Lee, H.-J., Kim, K.-B., Ko, Y.-G., Yoon, G., Lee, Y.-S., Hong, S.-I., & Lee, J.-S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4042 · Cited by 89
Regulation of transcription and chromatin structure by pRB: Here, there and everywhere
Talluri, S., & Dick, F. A. (2012) · Cell Cycle · doi:10.4161/cc.21263 · Cited by 88
Jiang, D., Brady, C. A., Johnson, T. M., Lee, E. Y., Park, E. J., Scott, M. P., & Attardi, L. D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111245108 · Cited by 86
“In contrast, p53-dependent senescence is thought to restrict development of lung cancers caused by Ras pathway activation (11) or prostate cancers caused by Pten loss (12).”
BackgroundSenescence-Associated MicroRNAs
Munk, R. B., Panda, A. C., Grammatikakis, I., Gorospe, M., & Abdelmohsen, K. (2017) · International review of cytology · doi:10.1016/bs.ircmb.2017.03.008 · Cited by 99
“Interestingly, the same oncogenes that can trigger senescence (e.g., KRAS(V12), BRAF (V600E)) can also trigger tumorigenesis if cells are unable to mount a senescent response (Braig et al., 2005; Collado et al., 2005; Dankort et al., 2009; Michaloglou et al., 2005).”
BackgroundSenescence induction; a possible cancer therapy
LLeonart, M. E., Artero-Castro, A., & Kondoh, H. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-3 · Cited by 87
“As the process of senescence is observed both in vitro and in vivo [2,7,22], tumor suppressor activation can be another target of cancer therapy in vivo.”
BackgroundMassive reshaping of genome-nuclear lamina interactions during oncogene-induced senescence.
Lenain, C., de Graaf, C. A., Pagie, L., Visser, N. L., de Haas, M., de Vries, S. S., Peric-Hupkes, D., van Steensel, B., & Peeper, D. S. (2017) · Genome Research · doi:10.1101/gr.225763.117 · Cited by 89
Cell-specific responses to loss of cyclin-dependent kinases
Berthet, C., & Kaldis, P. (2007) · Oncogene · doi:10.1038/sj.onc.1210243 · Cited by 97
“However, it has been shown by cell fusion experiments that senescence was dominant over immortality (Wadhwa et al., 1994; Bertram et al., 1999) and senescent cells can exist in premalignant tumors (Collado et al., 2005).”
BackgroundWagner, J., Damaschke, N., Yang, B., Truong, M., Guenther, C., McCormick, J., Huang, W., & Jarrard, D. (2015) · PLOS ONE · doi:10.1371/journal.pone.0124366 · Cited by 83
“This is consistent with other observations in premalignant tissues including melanotic naevi and mouse lung adenomas [5, 24].”
BackgroundResultSenescence and immortality in hepatocellular carcinoma
Öztürk, M., Arslan-Ergül, A., Baǧışlar, S., Şentürk, Ş., & Yuzugullu, H. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.10.048 · Cited by 105
A Role for CXCR2 in Senescence, but What about in Cancer?
Acosta, J. C., & Gil, J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3772 · Cited by 89
“Previously, these papillomas have been shown to be enriched in senescent cells (5).”
BackgroundSelf-citationDikovskaya, D., Cole, J. J., Mason, S. M., Nixon, C., Karim, S. A., McGarry, L., Clark, W., Hewitt, R. N., Sammons, M. A., Zhu, J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.07.055 · Cited by 89
“Cell Re called oncogene-induced senescence (OIS) (Braig et al., 2005; Chen et al., 2005; Collado et al., 2005; Michaloglou et al., 2005).”
BackgroundCellular Senescence and the Kidney: Potential Therapeutic Targets and Tools
Knoppert, S. N., Valentijn, F. A., Nguyen, T. Q., Goldschmeding, R., & Falke, L. L. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00770 · Cited by 83
“…2004; Freund et al., 2010) Expression of Dec1 [class E basic helix-loop-helix protein 40 (BHLHE40)] (Collado et al., 2005) Expression of DcR2 [TNF receptor superfamily member 10D (TNFRSF10D)] (Collado et al., 2005) 5 July 2019 | Volume 10 | Article 770Frontiers in Pharmacology | www.frontiersin.org”
BackgroundBack, J. H., Rezvani, H. R., Zhu, Y., Guyonnet‐Dupérat, V., Athar, M., Ratner, D., & Kim, A. L. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.240598 · Cited by 99
Vervloessem, T., Yule, D. I., Bultynck, G., & Parys, J. B. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.12.006 · Cited by 97
“As such, cellular senescence, in addition to apoptosis, is one of the pathways that counteract cancer cell initiation and tumour development [185, 186].”
BackgroundSantoriello, C., Deflorian, G., Pezzimenti, F., Kawakami, K., Lanfrancone, L., d’Adda di Fagagna, F., & Mione, M. (2009) · Disease Models & Mechanisms · doi:10.1242/dmm.001016 · Cited by 87
“Oncogene-induced senescence (OIS) has been demonstrated in cells that overexpress H-RAS (Serrano et al., 1997) and in several benign tumors (Collado et al., 2005).”
Dormant cancer cells: programmed quiescence, senescence, or both?
Truskowski, K., Amend, S. R., & Pienta, K. J. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10073-z · Cited by 92
p16INK4a as a Second Effector of the Telomere Damage Pathway
Jacobs, J. J. L., & de Lange, T. (2005) · Cell Cycle · doi:10.4161/cc.4.10.2104 · Cited by 87
Mazzoni, M., Mauro, G., Erreni, M., Romeo, P., Minna, E., Vizioli, M. G., Belgiovine, C., Rizzetti, M. G., Pagliardini, S., Avigni, R., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1198-8 · Cited by 91
Rajani, C., Borisa, P., Karanwad, T. R., Borade, Y., Patel, V., Rajpoot, K., & Tekade, R. K. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814527-2.00007-x · Cited by 95
Colucci, M., Zumerle, S., Bressan, S., Gianfanti, F., Troiani, M., Valdata, A., D’Ambrosio, M., Pasquini, E., Varesi, A., Cogo, F., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.02.004 · Cited by 93
“5,8,9 On the one hand, it prompts the immune system toward a robust clearance of the senescent cells.”
BackgroundLiu, B., Peng, Z., Zhang, H., Zhang, N., Liu, Z., Xia, Z., Huang, S., Luo, P., & Cheng, Q. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02284-z · Cited by 105
Bandyopadhyay, D., Curry, J. L., Lin, Q., Richards, H. W., Chen, D., Hornsby, P. J., Timchenko, N. A., & Medrano, E. E. (2007) · Aging Cell · doi:10.1111/j.1474-9726.2007.00308.x · Cited by 82
“Aging Cell (2007) 6 , pp577–591 Doi: 10.1111/j.1474-9726.2007.00308.x © 2007 The Authors 577 Journal compilation © Blackwell Publishing Ltd/Anatomical Society of Great Britain and Ireland 2007 Blackwell Publishing Ltd Dynamic assembly of chromatin complexes during cellular senescence: implications for the growth arres…”
BackgroundInfluentialRoediger, J., Hessenkemper, W., Bartsch, S., Manvelyan, M., Huettner, S. S., Liehr, T., Esmaeili, M., Foller, S., Petersen, I., Grimm, M., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-214 · Cited by 96
Senescence-Associated Pro-inflammatory Cytokines and Tumor Cell Plasticity
Vernot, J. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00063 · Cited by 86
“Currently, it is believed that cancer cell senescence override is necessary for full malignancy (Collado et al., 2005; Ohashi et al., 2010).”
BackgroundTumor suppression by p53: making cells senescent.
Qian, Y., & Chen, X. (2010) · PubMed · doi:10.14670/hh-25.515 · Cited by 85
“In addition, DEC1 is a novel senescence marker which is upregulated in oncogene K-rasV12-induced senescence (Collado et al., 2005).”
p38α and p38γ Mediate Oncogenic ras-induced Senescence through Differential Mechanisms
Kwong, J., Hong, L., Liao, R., Deng, Q., Han, J., & Sun, P. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808327200 · Cited by 82
Exploiting tumor cell senescence in anticancer therapy
Lee, M., & Lee, J.-S. (2014) · BMB Reports · doi:10.5483/bmbrep.2014.47.2.005 · Cited by 83
Camps, J., Grade, M., Nguyen, Q. T., Hörmann, P., Becker, S., Hummon, A. B., Rodriguez, V., Chandrasekharappa, S. C., Chen, Y., Difilippantonio, M. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2864 · Cited by 90
Oskarsson, T., Essers, M. A. G., Dubois, N., Offner, S., Dubey, C., Roger, C., Metzger, D., Chambon, P., Hummler, E., Beard, P., et al. (2006) · Genes & Development · doi:10.1101/gad.381206 · Cited by 82
“However, this cell cycle induction is coupled to the up-regulation of cell cycle inhibitors such as p15INK4b, p16INK4a, and p21Cip1, which under certain conditions can lead to cell cycle arrest and senescence (Serrano et al. 1997; Dajee et al. 2003; Braig et al. 2005; Collado et al. 2005).”
BackgroundNoncatalytic Function of ERK1/2 Can Promote Raf/MEK/ERK-mediated Growth Arrest Signaling
Hong, S.-K., Yoon, S., Moelling, C., Arthan, D., & Park, J.-I. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.012591 · Cited by 83
Cellular senescence: a hitchhiker’s guide
Aravinthan, A. (2015) · Human Cell · doi:10.1007/s13577-015-0110-x · Cited by 72
“Overexpression of oncogenes, or their downstream effectors, has been shown to cause premature senescence in both in vitro [61-63] and in vivo models [11, 64-66].”
BackgroundDifferential Regulation and Predictive Potential of MacroH2A1 Isoforms in Colon Cancer
Sporn, J. C., & Jung, B. H. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.02.027 · Cited by 87
Dysregulated glycolysis as an oncogenic event
Mikawa, T., LLeonart, M. E., Takaori‐Kondo, A., Inagaki, N., Yokode, M., & Kondoh, H. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1840-3 · Cited by 89
“In vivo, cellular senescence forms a protective barrier against immortalisation [37].”
BackgroundBarreto-Andrade, J. C., Efimova, E. V., Mauceri, H. J., Beckett, M. A., Sutton, H. G., Darga, T. E., Vokes, E. E., Posner, M. C., Kron, S. J., & Weichselbaum, R. R. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0061 · Cited by 87
Therapeutic targeting of replicative immortality
Yaswen, P., MacKenzie, K. L., Keith, W. N., Hentosh, P., Rodier, F., Zhu, J., Firestone, G. L., Matheu, A., Carnero, A., Bilsland, A. E., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.007 · Cited by 97
“[86] Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M, et al.”
BackgroundArtero‐Castro, A., Callejas, F. D. B., Castellví, J., Kondoh, H., Carnero, A., Fernández-Marcos, P. J., Serrano, M., y Cajal, S. R., & LLeonart, M. E. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01386-08 · Cited by 86
“Interestingly, senescent cells have recently been detected in human tumors, particularly in benign lesions (6, 15); senescence is thus an antitumorigenic mechanism developed by mammalian cells to avoid cell proliferation when any genetic alteration has occurred.”
BackgroundSelf-citationIs cellular senescence an example of antagonistic pleiotropy?
Giaimo, S., & d’Adda di Fagagna, F. (2012) · Aging Cell · doi:10.1111/j.1474-9726.2012.00807.x · Cited by 77
“restraining the initial steps of cancerogenesis (Collado et al., 2005).”
BackgroundInfluentialKolesnichenko, M., Mikuda, N., Höpken, U. E., Kärgel, E., Uyar, B., Tufan, A. B., Milanovic, M., Sun, W., Krahn, I., Schleich, K., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2019104296 · Cited by 81
“The epigenetically controlled cell cycle cessation serves as a cell-autonomous barrier to tumor formation (Braig et al , 2005; Collado et al , 2005; Reimann et al , 2010).”
p53 DNA Binding Cooperativity Is Essential for Apoptosis and Tumor Suppression In Vivo
Timofeev, O., Schlereth, K., Wanzel, M., Braun, A., Nieswandt, B., Pagenstecher, A., Rosenwald, A., Elsässer, H.-P., & Stiewe, T. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.04.008 · Cited by 76
“p53-triggered senescence was also readily detected in premalignant tumors initiated by conditional expression of oncogenic Kras in mice and protected against progression to carcinomas (Collado et al., 2005).”
Backgroundα-Fucosidase as a novel convenient biomarker for cellular senescence
Hildebrand, D., Lehle, S., Borst, A., Haferkamp, S., Essmann, F., & Schulze-Osthoff, K. (2013) · Cell Cycle · doi:10.4161/cc.24944 · Cited by 79
Oncogene-Induced Senescence Does Not Require the p16INK4a or p14ARF Melanoma Tumor Suppressors
Haferkamp, S., Scurr, L. L., Becker, T. M., Frausto, M., Kefford, R. F., & Rizos, H. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.5 · Cited by 93
“, 1997), which is also seen in vivo during the early stages of human and mouse tumor development (Braig et al., 2005; Chen et al., 2005; Collado et al., 2005; Michaloglou et al., 2005; Gray-Schopfer et al., 2006).”
Background(2019) · doi:10.1101/2019.12.19.882225 · Cited by 81
Short-term gain, long-term pain: the senescence life cycle and cancer
Chan, A. S. L., & Narita, M. (2019) · Genes & Development · doi:10.1101/gad.320937.118 · Cited by 80
“Following the description of OIS in vitro, senescent cells harboring oncogenic mutations were observed to accumulate in premalignant lesions of various tissue types in both humans andmice (Braig et al. 2005; Chen et al. 2005; Collado et al. 2005; Narita and Lowe 2005; Lazzerini Denchi et al. 2005; Michaloglou et al. 2…”
BackgroundCaveolin-1, a master regulator of cellular senescence
Volonté, D., & Galbiati, F. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09875-w · Cited by 84
“Moreover, loss of lamin B1 [67], accumulation of lipofuscin [68], expression of decoy death receptor 2 (DCR2), and embryonic chondrocyte-expressed 1 (DEC1) [69] have been associatedwith cellular senescence.”
BackgroundLazorthes, S., Vallot, C., Briois, S., Aguirrebengoa, M., Thuret, J.-Y., Laurent, G. S., Rougeulle, C., Kapranov, P., Mann, C., Trouche, D., et al. (2015) · Nature Communications · doi:10.1038/ncomms6971 · Cited by 78
Lessons from senescence: Chromatin maintenance in non-proliferating cells
Rai, T. S., & Adams, P. D. (2012) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2011.07.014 · Cited by 71
Corpet, A., Olbrich, T., Gwerder, M., Fink, D., & Stucki, M. (2014) · Cell Cycle · doi:10.4161/cc.26988 · Cited by 71
Malavolta, M., Bracci, M., Santarelli, L., Sayeed, M. A., Pierpaoli, E., Giacconi, R., Costarelli, L., Piacenza, F., Basso, A., Cardelli, M., et al. (2018) · Mediators of Inflammation · doi:10.1155/2018/4159013 · Cited by 81
“Moreover, it appears to be downregulated in oncogene-induced senescence of transformed cell lines (in which senescence can be triggered by MEK activation) and upregulated when senescence is bypassed (GEO Accession: GDS1637, Profile GDS1637/201146_at) [67].”
Breaking news: high-speed race ends in arrest – how oncogenes induce senescence
Micco, R. D., Fumagalli, M., & di Fagagna, F. D. (2007) · Trends in Cell Biology · doi:10.1016/j.tcb.2007.07.012 · Cited by 94
Nakamura, M., Ohsawa, S., & Igaki, T. (2014) · Nature Communications · doi:10.1038/ncomms6264 · Cited by 79
Cell senescence in neuropathology: A focus on neurodegeneration and tumours
Carreno, G., Guiho, R., & Martinez‐Barbera, J. P. (2021) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12689 · Cited by 74
Unexpected Pieces to the Senescence Puzzle
Cichowski, K. M., & Hahn, W. C. (2008) · Cell · doi:10.1016/j.cell.2008.05.027 · Cited by 86
“Abundant recent work indicates that senescence serves as an important mechanism of tumor suppression that is activated in benign lesions (Braig et al., 2005; Chen et al., 2005; Collado et al., 2005; Courtois-Cox et al., 2006; Michaloglou et al., 2005).”
BackgroundThe Key Role of Calmodulin in KRAS-Driven Adenocarcinomas
Nussinov, R., Muratcioglu, S., Tsai, C.-J., Jang, H., Gursoy, A., & Keskin, O. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0165 · Cited by 78
“Endogenous oncogenic K-Ras triggers senescence alone, in the absence of RTK signaling (128).”
BackgroundmiR-137 Modulates a Tumor Suppressor Network-Inducing Senescence in Pancreatic Cancer Cells
Neault, M., Mallette, F. A., & Richard, S. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.01.068 · Cited by 85
“However, the induction of senescence following Ras activation also has proven to be an effective intrinsic tumor suppression mechanism (Braig et al., 2005; Chen et al., 2005; Collado et al., 2005; Michaloglou et al., 2005).”
BackgroundXu, M., Yu, Q., Subrahmanyam, R., Difilippantonio, M. J., Ried, T., & Sen, J. M. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01360-07 · Cited by 75
“From left to right, a normal chromosome 6 (left), a deleted chromosome 6 (right), a chromatid break on chromosome 11, and chromosome translocations illustrated by T(10;17) (left) and T(4;6) (right) are shown; centromere fusions were sometimes simple, containing material from the same chromosome, as in Rb(3.”
BackgroundInfluentialRare codons capacitate Kras-driven de novo tumorigenesis
Pershing, N. L. K., Lampson, B. L., Belsky, J. A., Kaltenbrun, E., MacAlpine, D. M., & Counter, C. M. (2015) · Journal of Clinical Investigation · doi:10.1172/jci77627 · Cited by 77
Yates, K. E., Korbel, G. A., Shtutman, M., Roninson, I. B., & DiMaio, D. (2008) · Aging Cell · doi:10.1111/j.1474-9726.2008.00411.x · Cited by 77
Mimeault, M., & Batra, S. K. (2008) · Ageing Research Reviews · doi:10.1016/j.arr.2008.12.001 · Cited by 86
The interferon regulated ubiquitin-like protein, ISG15, in tumorigenesis: Friend or foe?☆
Andersen, J. B., & HASSEL, B. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2006.10.001 · Cited by 82
“Senescence is a permanent growth arrest that is associated with telomeric shortening, and has recently been demonstrated to serve a tumor suppressor function in vivo [84–88].”
BackgroundRas-Induced Senescence and its Physiological Relevance in Cancer
DiMauro, T., & David, G. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910793357998 · Cited by 76
“These markers have been used to identify cells subjected to cellular senescence in human preneoplasic lesions or aging tissues [14,17].”
BackgroundSenescence-associated SIN3B promotes inflammation and pancreatic cancer progression
Rielland, M., Cantor, D. J., Graveline, R., Hajdu, C., Mara, L., de Diego Diaz, B., Miller, G., & David, G. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72619 · Cited by 76
BTK Modulates p53 Activity to Enhance Apoptotic and Senescent Responses
Althubiti, M., Rada, M., Samuel, J., Escorsa, J. M., Najeeb, H., Lee, K.-G., Lam, K., Jones, G. D. D., Barlev, N. A., & Macip, S. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0690 · Cited by 78
“Senescent cells are present in premalignant and early stages of solid cancers, after which they disappear, which suggests that the senescent barrier needs to be overcome in order to progress into malignancy (14).”
BackgroundTGF-β in the microenvironment induces a physiologically occurring immune-suppressive senescent state
Matsuda, S., Revandkar, A., Dubash, T. D., Ravi, A., Wittner, B. S., Lin, M., Morris, R. T., Burr, R., Guo, H., Seeger, K., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112129 · Cited by 84
“In cancer, senescence is documented under three settings: in premalignant states, 6 upon forced oncogene expression, 7 and in response to therapies.”
The controversial role of senescence-associated secretory phenotype (SASP) in cancer therapy
Cao, L., Li, K., Li, Q., Tong, Q., Wang, Y., & Huang, L. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02475-8 · Cited by 93
In vitro evidence for senescent multinucleated melanocytes as a source for tumor-initiating cells
Leikam, C., Hufnagel, A. L., Otto, C., Murphy, D. J., Mühling, B., Kneitz, S., Nanda, I., Schmid, M., Wagner, T. U., Haferkamp, S., et al. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.71 · Cited by 74
“precedes transformation, and tumors arise from senescent tissue.(1,5,6,9) However, as OIS was long considered to be”
BackgroundCarrière, C., Gore, A. J., Norris, A. M., Gunn, J. R., Young, A. L., Longnecker, D. S., & Korc, M. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.05.041 · Cited by 76
Epithelial cell senescence: an adaptive response to pre-carcinogenic stresses?
Abbadie, C., Pluquet, O., & Pourtier, A. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2587-9 · Cited by 83
Novel roles of Skp2 E3 ligase in cellular senescence, cancer progression, and metastasis
Wang, G., Chan, C., Gao, Y., & Lin, H. (2011) · 癌症:英文版 · doi:10.5732/cjc.011.10319 · Cited by 83
Hasegawa, H., Yamada, Y., Iha, H., Tsukasaki, K., Nagai, K., Atogami, S., Sugahara, K., Tsuruda, K., Ishizaki, A., & Kamihira, S. (2009) · Leukemia · doi:10.1038/leu.2009.171 · Cited by 85
Pro- and anti-tumorigenic functions of the senescence-associated secretory phenotype
Lau, L., & David, G. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1565658 · Cited by 70
The Regulation of Cellular Functions by the p53 Protein: Cellular Senescence
Tonnessen-Murray, C. A., Lozano, G., & Jackson, J. G. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026112 · Cited by 70
“Lung adenomas were positive for the senescence markers p16, p15, and new markers discovered in the same study, Dec1 and Dcr2 (Collado et al. 2005).”
BackgroundKim, Y. Y., Um, J., Yoon, J.-H., Lee, D., Lee, Y. J., Kim, D. H., Park, J., & Yun, J. (2019) · The FASEB Journal · doi:10.1096/fj.201901747rr · Cited by 77
The emerging role of p53 in stem cells
Bonizzi, G., Cicalese, A., Insinga, A., & Pelicci, P. G. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.08.002 · Cited by 78
p53 Mediates Senescence-Like Arrest Induced by Chronic Replicational Stress
Marusyk, A., Wheeler, L. J., Mathews, C. K., & DeGregori, J. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01316-06 · Cited by 74
“Recently, the induction of senescence has been revealed as an important physiological block to tumorigenesis induced by oncogene activation (8, 20, 22, 61).”
BackgroundSETD1A protects from senescence through regulation of the mitotic gene expression program
Tajima, K., Matsuda, S., Yae, T., Drapkin, B. J., Morris, R. T., Boukhali, M., Niederhoffer, K., Comaills, V., Dubash, T. D., Nieman, L. T., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10786-w · Cited by 75
Misawa, T., Tanaka, Y., Okada, R., & Takahashi, A. (2020) · Geriatrics & Gerontology International · doi:10.1111/ggi.13928 · Cited by 69
Liu, Y., Lomeli, I., & Kron, S. J. (2024) · Cells · doi:10.3390/cells13151281 · Cited by 77
“In cancer, SnCs can originate from different sources and are detected in premalignant lesions as well as within the TME during different phases of cancer initiation, progression, and therapy response [44,45].”
BackgroundHuang, B., Deo, D., Xia, M., & Vassilev, L. T. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0144 · Cited by 72
“Primary antibodies used are as follows: p53 (sc-263) and MDM2 (sc-965) were from Santa Cruz Biotechnology; p21 (OP64) from Calbiochem, human MDMX (A300-287A-1) from Bethyl Laboratories; β-actin (AC-74) from Sigma; Rb, phospho-Rb, and Mouse Antip15INK4b from Cell Signaling; and E2F1, p107, p130, and DcR2 antibody (sc-1…”
BackgroundMolecular Network Associated with MITF in Skin Melanoma Development and Progression
Yajima, I., Kumasaka, M. Y., Thang, N. D., Goto, Y., Takeda, K., Iida, M., Ohgami, N., Tamura, H., Yamanoshita, O., Kawamoto, Y., et al. (2011) · Journal of Skin Cancer · doi:10.1155/2011/730170 · Cited by 82
Ground-glass nodules of the lung in never-smokers and smokers: clinical and genetic insights
Kobayashi, Y., Ambrogio, C., & Mitsudomi, T. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.07.04 · Cited by 75
“Oncogenic Ras has been shown to cause senescence through the activation of the p53-p21 WAF and p16INK4ARetinoblastoma tumor-suppressor pathways (27,28).”
BackgroundThe thorny path linking cellular senescence to organismal aging
Patil, C. K., Mian, S. I., & Campisi, J. (2005) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2005.08.001 · Cited by 85
“…recent findings indicate that the malignant progression of cells with potentially oncogenic mutations is suppressed by the senescence response, and that this suppression occurs in both mice and humans in vivo (Braig et al., 2005; Chen et al., 2005; Collado et al., 2005; Michaloglou et al., 2005).”
DNA damage-induced cellular senescence is sufficient to suppress tumorigenesis: a mouse model
Van Nguyen, T., Puebla-Osorio, N., Pang, H., Dujka, M. E., & Zhu, C. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062453 · Cited by 72
“An example of these proteins is the heterochromatin protein 1 (HP1) family member HP1γ, which has been established as a marker for senescence-associated heterochromatin foci (SAHF) (20) in human (21) and murine cells (22).”
BackgroundYAP1‐LATS2 feedback loop dictates senescent or malignant cell fate to maintain tissue homeostasis
He, C., Lv, X., Huang, C., Hua, G., Ma, B., Chen, X., Angeletti, P. C., Dong, J., Zhou, J. R., Wang, Z., et al. (2019) · EMBO Reports · doi:10.15252/embr.201744948 · Cited by 79
Premature aging/senescence in cancer cells facing therapy: good or bad?
Calvo, L., Ghadaouia, S., Martinez, A., & Rodier, F. (2015) · Biogerontology · doi:10.1007/s10522-015-9593-9 · Cited by 82
Large liver cell change in hepatitis B virus–related liver cirrhosis #
Kim, H., Oh, B.-K., Roncalli, M. G., Park, C., Yoon, S.-M., Yoo, J. E., & Park, Y. N. (2009) · Hepatology · doi:10.1002/hep.23072 · Cited by 77
A functional genetic screen defines the AKT-induced senescence signaling network
Chan, K. T., Blake, S., Zhu, H., Kang, J., Trigos, A. S., Madhamshettiwar, P. B., Diesch, J., Paavolainen, L., Horvath, P., Hannan, R. D., et al. (2020) · Cell Death & Differentiation · doi:10.1038/s41418-019-0384-8 · Cited by 71
Geserick, C., Tejera, Á. M., González‐Suárez, E., Klatt, P., & Blasco, M. A. (2006) · Oncogene · doi:10.1038/sj.onc.1209465 · Cited by 83
“Indeed, qRT–PCR analysis of expression of the TGF-b effector JunB in kidneys from mTert-overexpressing mice revealed a 2.572.1-fold repression (n¼ 4) of JunB levels as Oncogene Table 1 Genes regulated by mTert overexpression in MEFs Affymetrix probe number Gene expression change (-fold) Gene symbol Gene name Gene onto…”
BackgroundInfluentialInactivation of TGF-β signaling and loss of PTEN cooperate to induce colon cancer in vivo
Yu, M., Trobridge, P. A., Wang, Y., Kanngurn, S., Morris, S. M., Knoblaugh, S. E., & Grady, W. M. (2013) · Oncogene · doi:10.1038/onc.2013.102 · Cited by 76
Cdk2: a key regulator of the senescence control function of Myc
Hydbring, P., & Larsson, L. (2010) · Aging · doi:10.18632/aging.100140 · Cited by 81
“Cellular senescence has been demonstrated in different types of premalignant tumor cells in vivo during recent years, and has emerged as an important tumorsuppressive mechanism [3,4,5,6,7].”
BackgroundS-adenosylhomocysteine hydrolase downregulation contributes to tumorigenesis
Martínez-Leal, J. F., Ferrer, I., Blanco‐Aparicio, C., Hernández‐Losa, J., y Cajal, S. R., Carnero, A., & LLeonart, M. E. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn198 · Cited by 75
Wu, P.-K., Hong, S.-K., Veeranki, S., Karkhanis, M., Starenki, D., Plaza, J. A., & Park, J.-I. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00021-13 · Cited by 69
Targeting tumor cell senescence and polyploidy as potential therapeutic strategies
Saleh, T., Carpenter, V. J., Bloukh, S., & Gewirtz, D. A. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.12.010 · Cited by 74
Wnt signaling potentiates nevogenesis
Pawlikowski, J. S., McBryan, T., van Tuyn, J., Drotar, M. E., Hewitt, R. N., Maier, A. B., King, A., Blyth, K., Wu, H., & Adams, P. D. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303491110 · Cited by 68
“Senescence of BRAF-expressing cells was confirmed by flattened morphology, cell cycle exit (repression of cyclin A, suppression of 5′-BrdU incorporation, and pRB hypophosphorylation), expression of Dec1 (6), appearance of senescence-associated heterochromatin foci (SAHF) (34), and expression of SA β-gal (Fig.”
BackgroundPre-Invasive Ovarian Mucinous Tumors Are Characterized by CDKN2A and RAS Pathway Aberrations
Hunter, S. M., Gorringe, K. L., Christie, M., Rowley, S. M., Bowtell, D. D. L., Chenevix‐Trench, G., & Campbell, I. G. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1103 · Cited by 69
Rac1 GTPase Regulates Cell Genomic Stability and Senescence
Debidda, M., Williams, D. A., & Zheng, Y. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604607200 · Cited by 66
Geroconversion of aged muscle stem cells under regenerative pressure
Sousa-Victor, P., Perdiguero, E., & Muñoz-Cánoves, P. (2014) · Cell Cycle · doi:10.4161/15384101.2014.965072 · Cited by 68
Lee, S. Y., Ju, M. K., Jeon, H. M., Lee, Y. J., Kim, C. H., Park, H. G., Han, S. I., & Kang, H. S. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/1027453 · Cited by 71
Metadata
- Authors
- Collado, M., Gil, J., Efeyan, A., Guerra, C., Schuhmacher, A. J., Barradas, M., Benguría, A., Zaballos, A., Flores, J. M., Barbacid, M., Beach, D., & Serrano, M.
- Affiliations
- Spanish National Cancer Research Centre (ES)
- Imperial College London (GB)
- Consejo Superior de Investigaciones Científicas (ES)
- Universidad Complutense de Madrid (ES)
- Corresponding author
- Serrano, Manuel
- ORCID
- Venue
- Nature
- Published
- 2005-08-04
- Volume
- 436
- Issue
- 7051
- Pages
- 642-642
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2067117191
- Cited by
- 1,482
- References
- 7
- Citations by year
- 2026: 31 · 2025: 40 · 2024: 59 · 2023: 58 · 2022: 57 · 2021: 74 · 2020: 87 · 2019: 55 · 2018: 53 · 2017: 68 · 2016: 67 · 2015: 73 · 2014: 76 · 2013: 81 · 2012: 81
- FWCI
- 46.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Keywords
- cellular senescence, oncogene-induced senescence, oncogenic Ras, lymphoma, SUV39H1, histone methyltransferase, epigenetic regulation, melanoma, p53, PTEN mutation, prostate cancer, tumor suppression, cancer diagnosis and prognosis
- MeSH terms
- Adenocarcinoma, Alleles, Animals, beta-Galactosidase, Cell Transformation, Neoplastic, Disease Models, Animal, Heterochromatin, Lung Neoplasms, Mice, Transgenic, Precancerous Conditions, Genes, ras, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, Cellular Senescence, Disease Progression, Cyclin-Dependent Kinase Inhibitor p16, Oligonucleotide Array Sequence Analysis, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.